V
Velimir A. Luketic
Researcher at Virginia Commonwealth University
Publications - 211
Citations - 21732
Velimir A. Luketic is an academic researcher from Virginia Commonwealth University. The author has contributed to research in topics: Cirrhosis & Liver transplantation. The author has an hindex of 68, co-authored 203 publications receiving 19475 citations. Previous affiliations of Velimir A. Luketic include VCU Medical Center & University of California, Los Angeles.
Papers
More filters
Journal ArticleDOI
Nonalcoholic Steatohepatitis: Association of Insulin Resistance and Mitochondrial Abnormalities
Arun J. Sanyal,Carol Campbell-Sargent,Faridoddin Mirshahi,William B. Rizzo,Melissa J. Contos,Richard K. Sterling,Velimir A. Luketic,Mitchell L. Shiffman,John N. Clore +8 more
TL;DR: Data indicate that peripheral insulin resistance, increased fatty acid beta oxidation, and hepatic oxidative stress are present in both fatty liver and NASH, but NASH alone is associated with mitochondrial structural defects.
Journal ArticleDOI
Clinical and histologic spectrum of nonalcoholic fatty liver disease associated with normal ALT values
Pouneh S. Mofrad,Melissa J. Contos,Mahmadul Haque,Carol Sargeant,Robert A. Fisher,Velimir A. Luketic,Richard K. Sterling,Mitchell L. Shiffman,Richard T. Stravitz,Arun J. Sanyal +9 more
TL;DR: The entire histologic spectrum of NAFLD can be seen in individuals with normal ALT values, and the Histologic spectrum in these individuals is not significantly different from those with elevated ALT levels, which means a lownormal ALT value does not guarantee freedom from underlying steatohepatitis with advanced fibrosis.
Journal ArticleDOI
Elafibranor, an Agonist of the Peroxisome Proliferator−Activated Receptor−α and −δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening
Vlad Ratziu,Vlad Ratziu,Stephen A. Harrison,Sven Francque,Pierre Bedossa,Philippe Lehert,Philippe Lehert,Lawrence Serfaty,Manuel Romero-Gómez,Jérôme Boursier,Manal F. Abdelmalek,Steve Caldwell,Joost P.H. Drenth,Quentin M. Anstee,Dean W. Hum,Rémy Hanf,A. Roudot,S. Megnien,Bart Staels,Arun J. Sanyal,Philippe Mathurin,J. Gournay,Eric Nguyen-Khac,V. de Ledinghen,Dominique Larrey,A. Tran,M. Bourliere,M. Maynard-Muet,Tarik Asselah,Jean Henrion,Frederik Nevens,David Cassiman,Albert Geerts,Christophe Moreno,Ulrich Beuers,Peter R. Galle,Ulrich Spengler,Elisabetta Bugianesi,Antonio Craxì,Mario Angelico,Silvia Fargion,M. Voiculescu,Liana Gheorghe,L. Preotescu,Juan Caballería,Raúl J. Andrade,Javier Crespo,J. L. Callera,Aftab Ala,Guruprasad P. Aithal,G. Abouda,Velimir A. Luketic,M. A. Huang,Stuart C. Gordon,Paul J. Pockros,Fred Poordad,N. Shores,M. W. Moehlen,Kiran Bambha,V. Clark,Sanjaya K. Satapathy,S. Parekh,R. K. Reddy,Muhammad Y. Sheikh,Gyongyi Szabo,John M. Vierling,T. Foster,Guillermo E. Umpierrez,C. Chang,Terry Box,J. Gallegos-Orozco +70 more
TL;DR: A post-hoc analysis of data from trial of patients with NASH showed that elafibranor (120 mg/d for 1 year) resolved NASH without fibrosis worsening, based on a modified definition, in the intention-to-treat analysis and in patients with moderate or severe NASH.
Journal ArticleDOI
A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis
Frederik Nevens,Pietro Andreone,Giuseppe Mazzella,Simone I. Strasser,Christopher L. Bowlus,Pietro Invernizzi,J.P.H. Drenth,Paul J. Pockros,Jaroslaw Regula,Ulrich Beuers,Michael Trauner,David Jones,Annarosa Floreani,Simon Hohenester,Velimir A. Luketic,Mitchell L. Shiffman,K.J. van Erpecum,Victor Vargas,Catherine Vincent,Gideon M. Hirschfield,Hemant Shah,Bettina E. Hansen,Keith D. Lindor,Hanns-Ulrich Marschall,Kris V. Kowdley,R. Hooshmand-Rad,T. Marmon,S. Sheeron,R. Pencek,Leigh MacConell,Mark Pruzanski,David Shapiro +31 more
TL;DR: Obeticholic acid administered with ursodiol or as monotherapy for 12 months in patients with primary biliary cholangitis resulted in decreases from baseline in alkaline phosphatase and total bilirubin levels that differed significantly from the changes observed with placebo.
Journal ArticleDOI
Nonalcoholic steatohepatitis is associated with altered hepatic MicroRNA expression.
Onpan Cheung,Puneet Puri,Christoph Eicken,Melissa J. Contos,Faridoddin Mirshahi,James W. Maher,John M. Kellum,Hae-Ki Min,Velimir A. Luketic,Arun J. Sanyal +9 more
TL;DR: NASH is associated with altered hepatic microRNA expression and underexpression of miR‐122 potentially contributes to altered lipid metabolism implicated in the pathogenesis of NASH.